S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

TherapeuticsMD Stock Forecast, Price & News

+0.01 (+0.10%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
635,159 shs
Average Volume
656,055 shs
Market Capitalization
$87.85 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

TXMD Stock Forecast (MarketRank)

Overall MarketRank

1.66 out of 5 stars

Medical Sector

947th out of 1,432 stocks

Pharmaceutical Preparations Industry

474th out of 685 stocks

Analyst Opinion: 3.2Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
TherapeuticsMD logo

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$-172.41 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$86.95 million
Book Value
($11.05) per share


Free Float
Market Cap
$87.85 million

TherapeuticsMD Frequently Asked Questions

Should I buy or sell TherapeuticsMD stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TherapeuticsMD stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View analyst ratings for TherapeuticsMD
or view top-rated stocks.

What is TherapeuticsMD's stock price forecast for 2022?

3 Wall Street analysts have issued 12 month price targets for TherapeuticsMD's stock. Their TXMD stock forecasts range from $125.00 to $250.00. On average, they predict TherapeuticsMD's stock price to reach $187.50 in the next twelve months. This suggests a possible upside of 1,788.2% from the stock's current price.
View analysts' price targets for TherapeuticsMD
or view top-rated stocks among Wall Street analysts.

How has TherapeuticsMD's stock performed in 2022?

TherapeuticsMD's stock was trading at $17.7750 on January 1st, 2022. Since then, TXMD shares have decreased by 44.1% and is now trading at $9.93.
View the best growth stocks for 2022 here

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for TherapeuticsMD

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its quarterly earnings data on Monday, May, 16th. The company reported ($5.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.50) by $2.19. During the same quarter in the previous year, the company earned ($5.50) EPS.
View TherapeuticsMD's earnings history

When did TherapeuticsMD's stock split? How did TherapeuticsMD's stock split work?

TherapeuticsMD shares reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of TherapeuticsMD stock prior to the reverse split would have 2 shares after the split.

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the following people:
  • Mr. Hugh O'Dowd M.B.A., Pres, CEO & Director (Age 56, Pay $1.19M)
  • Mr. Robert G. Finizio, Co-Founder (Age 51, Pay $2.53M) (LinkedIn Profile)
  • Mr. Marlan D. Walker J.D., Gen. Counsel & Secretay (Age 47, Pay $506.21k)
  • Mr. John C. K. Milligan IV, Chief Exec. Officer of VitaCare Prescription Services (Age 60, Pay $606.1k)
  • Dr. Brian A. Bernick F.A.C.O.G., M.D., Co-Founder and Chief Scientific & Medical Officer (Age 54)
  • Mr. Michael C. Donegan, Interim CFO, Chief Accounting Officer and Principal Financial & Accounting Officer (Age 54)
  • Ms. Daniella Silva, Chief Compliance Officer (Age 36)
  • Mr. Benjamin Foulk, VP of HR (Age 52)
  • Mr. Mitchell L. Krassan, Exec. VP and Chief Strategy & Performance Officer (Age 56)
  • Ms. Julia M. Amadio, Chief Product Officer

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $9.93.

How much money does TherapeuticsMD make?

TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $87.85 million and generates $86.95 million in revenue each year. The company earns $-172.41 million in net income (profit) each year or ($21.690010) on an earnings per share basis.

How many employees does TherapeuticsMD have?

TherapeuticsMD employs 416 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for TherapeuticsMD is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at [email protected], or via fax at 561-431-3389.

This page (NASDAQ:TXMD) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.